Advertise on podcast: CME in Minutes: Education in Oncology & Hematology

Please visit answersincme.com/860/IME-26-0163-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Véronique Diéras, MD; Peter A. Fasching, MD; and Sara A. Hurvitz, MD, FACP. In this activity, experts in breast cancer discuss evidence and implementation of first-line treatment options, including novel regimens, for HER2-positive metastatic disease. Upon completion of this activity, participants should be better able to: Specify first-line treatment recommendations for patients with HER2-positive unresectable or metastatic breast cancer (mBC); Assess the evidence for novel recommended first-line therapy regimens for HER2-positive mBC; Determine which patients with HER2-positive mBC are candidates for various recommended first-line therapies according to patient, treatment, and disease factors; and Formulate strategies to optimally manage care for patients on novel first-line treatment regimens for HER2-positive mBC.

Please visit answersincme.com/860/MED-ONC-03731-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sunandana Chandra, MD, MS; Vishal A. Patel, MD; Vernon K. Sondak, MD; and Jessica Kalen, MD, FAAD. In this activity, experts in skin cancer discuss the current use of immunotherapy-based treatment approaches in resectable cutaneous squamous cell carcinoma (CSCC), with a focus on the role of dermatologists in the multidisciplinary team. Upon completion of this activity, participants should be better able to: Outline guideline-recommended clinical approaches for the management of patients with early-stage CSCC; Specify key real-world considerations that influence the appropriate use of neoadjuvant and adjuvant immunotherapy in resectable CSCC, within the context of multidisciplinary care; and Formulate a collaborative care plan that defines the roles and responsibilities of multidisciplinary team members to optimize outcomes for patients with resectable CSCC who are candidates for neoadjuvant and/or adjuvant immunotherapy. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/860/104092969-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO; and Jesus Berdeja, MD. In this activity, experts in hematology-oncology discuss the evolving role of cereblon E3 ligase modulators (CELMoDs) in patients with relapsed/refractory multiple myeloma (RRMM). Upon completion of this activity, participants should be better able to: Identify the role of CELMoDs in the treatment of patients with RRMM. Utilize evidence-based practical strategies for the management of key adverse events associated with CELMoDs in patients with RRMM. Apply key considerations to support the integration of CELMoDs into the treatment paradigm for patients with RRMM.

Please visit answersincme.com/860/2026-MC-002375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO; and Krina Patel, MD, MSc. In this activity, experts in multiple myeloma discuss key treatment considerations and personalization strategies for anti-CD38 therapy. Upon completion of this activity, participants should be better able to: Evaluate the clinical implications of key data supporting anti-CD38–based regimens in patients with multiple myeloma (MM); Outline evidence-based strategies to manage toxicities associated with anti-CD38–based therapies; Identify key considerations for integrating anti-CD38 monoclonal antibodies into treatment plans for patients with MM; and Apply practical, patient-centered care considerations to optimize outcomes with anti-CD38 monoclonal antibodies for patients with MM.

Please visit answersincme.com/CJF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Manuel Rodriguez-Justo, MBBCh, MSc, MD, FRCPath; and Elizabeth Smyth, MD, FRCP. In this activity, experts in oncology and pathology discuss the impact of claudin 18.2 (CLDN18.2) tests and treatments for patients with advanced gastric or gastroesophageal junction cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for CLDN18.2 testing in patients with advanced gastric and gastroesophageal junction cancers (GC/GEJC); Review the potential clinical impact of emerging CLDN18.2-targeted antibody-drug conjugates (ADCs) for the treatment of GC/GEJC; and Outline evidence-based, emerging strategies to optimize outcomes in patients with advanced GC/GEJC.

Please visit answersincme.com/MSM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ritu Salani, MD; and Courtney Arn, CNP. In this activity, experts in gynecological oncology discuss antibody-drug conjugates (ADCs) in ovarian, cervical, and endometrial cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for using ADCs in previously treated patients with gynecologic cancers; Assess the safety and tolerability evidence for approved ADC therapies in gynecologic cancers; Formulate management strategies for adverse events associated with ADC treatment of ovarian, cervical, and endometrial cancers; and Outline patient-centered approaches to facilitate adherence with ADC therapy.

Please visit answersincme.com/WAY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Elizabeth O'Donnell, MD. In this activity, an expert in multi-cancer early detection (MCED) discusses strategies to apply MCED testing into everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the benefits and risks of MCED testing; and Outline patient-centered strategies to appropriately incorporate MCED testing into the primary care setting.

Please visit answersincme.com/860/cvdprostate-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michael Cookson, MD; Alicia Morgans, MD, MPH; and Avirup Guha, MD, MBBS, MPH, FAHA, FACC, FESC, FICOS. In this activity, experts in prostate cancer discuss cardiovascular risk in patients receiving androgen-deprivation therapy (ADT). Upon completion of this activity, participants should be better able to: Evaluate the impacts of prostate cancer and ADT on cardiovascular risk; Translate the latest research for cardiovascular management of patients on ADT to clinical practice; and Design personalized treatment approaches to optimize ADT across treatment settings.

Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.

Please visit answersincme.com/KNY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Barbara Melosky, MD, FRCPC; and Alyson Chin, RN, BScN, MN-ACNP(A). In this activity, experts in lung cancer discuss the management of adverse events associated with tyrosine kinase inhibitor use in patients with ALK-positive metastatic non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Identify ALK tyrosine kinase inhibitor (TKI)–related adverse events (AEs) among patients with ALK-positive (ALK+) metastatic non–small-cell lung cancer (mNSCLC); Apply strategies to effectively monitor and manage ALK TKI–related AEs to enhance treatment adherence in patients with ALK+ mNSCLC; and Outline multidisciplinary, patient-centered strategies to optimize care for patients receiving ALK TKIs for ALK+ mNSCLC.

Please visit answersincme.com/RVH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vivien Brown, MDCM, CCFP, FCFP, MSCP. In this activity, an expert in menopause management in primary care discusses identification and treatment of menopause-related vasomotor symptoms (VMS). Upon completion of this activity, participants should be better able to: Integrate communication about menopause and VMS into routine patient encounters; Review treatment options for moderate to severe VMS, including NK receptor antagonists, with patients using a shared decision-making approach; and Formulate strategies for optimally monitoring patients who are receiving NK receptor antagonists for menopause-related VMS.

Please visit answersincme.com/JKK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alison J. Birtle, FRCP, FRCR, MD; and Niklas Klümper, MD. In this activity, experts in oncology discuss systemic therapies for locally advanced and metastatic urothelial carcinoma. Upon completion of this activity, participants should be better able to: Assess the evidence for recommended systemic treatment regimens for patients with LA/mUC in the context of treatment guidelines; Propose appropriate patient assessment strategies to guide systemic therapy decisions; and Formulate individualized treatment strategies to optimize outcomes for patients with LA/mUC using recommended first-line systemic treatments.

Please visit answersincme.com/NDX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tycel J. Phillips, MD and Steven Horwitz, MD. In this activity, experts in B-cell and T-cell lymphomas discuss EZH inhibitors for non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Discuss the rationale for EZH inhibitors in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL); Describe the clinical profiles of available and emerging EZH inhibitors; and Outline current and potential methods of optimizing EZH inhibitors in clinical practice based on available evidence.

Please visit answersincme.com/ZGK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Amer Zeidan, MBBS, MHS. In this activity, an expert in myelodysplastic syndromes (MDS) discusses approaches to optimize management of anemia in lower-risk MDS. Upon completion of this activity, participants should be better able to: Translate the latest clinical trial data to the management of patients with lower-risk MDS; Evaluate evidence-based strategies for optimizing the use of available agents in lower-risk MDS; and Design treatment plans that effectively sequence available therapies in patients with lower-risk MDS.

Please visit answersincme.com/XUG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sara A. Hurvitz, MD, FACP. In this activity, an expert in breast cancer discusses the evidence for TROP2-directed antibody-drug conjugates in metastatic triple-negative disease (mTNBC). Upon completion of this activity, participants should be better able to: Review the clinical impact of TROP2-directed antibody-drug conjugates (ADCs) for the management of mTNBC; Evaluate the clinical implications of the evidence exploring first-line use of TROP2 ADCs in combination with immunotherapy for mTNBC; and Develop an evidence-informed strategy that incorporates TROP2-directed ADCs and immunotherapy combinations into first-line management of mTNBC, where appropriate.